

International Symposium on Translational Research in Liver Cancer

- Advisor: Ministry of Health and Welfare
- Organizers: National Health Research Institutes; Health Innovation Center, National Yang Ming Chiao Tung University; Institute of Biomedical Informatics, National Yang Ming Chiao Tung University; Microbiota Research Center, National Yang Ming Chiao Tung University; National Human Microbiome Core Facility
- Date: 2024/8/24 (Saturday) 09:00~16:40-
- Venue: Ho Ying-Tsai Memorial Hall, Shou-Ren Building, National Yang Ming Chiao Tung University (No.155, Sec.2, Linong Street, Taipei, Taiwan)
- Agenda:

Time	Program		
9:00-9:15	Registration		
9:15-9:30	Opening Remarks	President Huey-Kang Sytwu, National Health Research Institutes 國家衛生研究院 司徒惠康院長	
		(TBD), Ministry of Health and Welfare 衛生福利部	
	Topic	Speaker	Moderator
9:30-10:00	Converging of Paradigm of Western and Eastern Medicine for Developing Future Medicine (WE Medicine) for The Treatment of Unmet Health Need Including Hepatocellular Carcinoma	Academician Yung-Chi Cheng, Yale University 耶魯大學 鄭永齊院士	President Huey-Kang Sytwu, National Health Research Institutes 國家衛生研究院 司徒惠康院長
10:00-10:30	Autophagy and Hepatocarcinogenesis	Academician Jing-Hsiung James Ou, University of Southern California 南加州大學 歐競雄院士	
10:30-11:00	Unmet Needs for HCC Control and Managements	Academician Pei-Jer Chen, National Taiwan University 國立臺灣大學 陳培哲院士	
11:00-11:20	Coffee break		
11:20-11:40	PSPC1 as the Contextual Determinants of HCC Tumor Progression	Distinguished Research Fellow Yuh-Shan Jou, Academia Sinica 中央研究院 周玉山特聘研究員	Chair Professor Jaw-Ching Wu, National Yang Ming Chiao Tung University 國立陽明交通大學 吳肇卿講座教授
11:40-12:00	HCC post HCV eradication: translational study in clinical unmet needs	President Ming-Lung Yu, Kaohsiung Medical University 高雄醫學大學 余明隆校長	
12:00-12:20	HCC 2 nd and 3 rd prevention: translation from evidence to health policy	Chair Professor/Director Chun-Ying Wu, National Yang Ming Chiao Tung University 國立陽明交通大學 吳俊穎講座教授	

12:20-13:30	Lunch Break		
13:30-13:50	Early Antiviral Treatment for Gray Zone CHB Patients with High HCC Risk is Critical to Achieve the Goal of Two Thirds Reduction of Liver-related Mortality by WHO Before 2030	Chair Professor Jaw-Ching Wu, National Yang Ming Chiao Tung University 國立陽明交通大學 吳肇卿講座教授	Acting Director Ko-Jiunn Liu, National Health Research Institutes 國家衛生研究院 劉柯俊執行長
13:50-14:10	Conventional and Machine-Learning Based Risk Score to Predict the Outcomes of Patients with Hepatocellular Carcinoma	Chief Chien-Wei Su, Taipei Veterans General Hospital 臺北榮民總醫院 蘇建維主任	
14:10-14:30	Risk Prediction for Liver Cancer in Patients with Chronic Viral Hepatitis	Vice Superintendent Yao-Chun Hsu, E-Da Hospital 義大醫院 許耀峻副院長	
14:30-14:50	Prediction the Outcome of Immunotherapy for HCC	Assistant Professor Wei Teng, Chang Gung University 長庚大學 滕威助理教授	
14:50-15:10	Coffee Break		
15:10-15:30	Risk stratification and HCC surveillance for MASH-related hepatocellular carcinoma	Assistant Professor Daniel Q. Huang, National University of Singapore	Chair Professor/Director Chun-Ying Wu, National Yang Ming Chiao Tung University 國立陽明交通大學 吳俊穎講座教授
15:30-15:50	The Impact of Metabolic-associated Steatotic Liver Disease on Chronic Hepatitis B-related Hepatocellular Carcinoma	Clinical Associate Professor Tung-Hung Su, National Taiwan University Hospital 國立臺灣大學附設醫院 蘇東弘副教授	
15:50-16:10	Evaluating the Risk of Hepatocellular Carcinoma in Patients with Non-alcoholic Fatty Liver Disease	Attending Physician Teng-Yu Lee, Taichung Veterans General Hospital 臺中榮民總醫院 李騰裕主治醫師	
16:10-16:30	Beyond Immune Checkpoint Inhibitors: New Trends of Cancer Immunotherapy Research	Professor Chiun Hsu, National Taiwan University 國立臺灣大學 許駿教授	
16:30-16:40	Closing Remarks	Chair Professor/Director Chun-Ying Wu, National Yang Ming Chiao Tung University 國立陽明交通大學 吳俊穎講座教授	